RxDoctor Payments Data

Daniel Kolansky, MD

Interventional Cardiology · Philadelphia, PANPI 1124054812

Payments from drug & device makers

$29,125in general payments, 2019–2025

Across 129 payments — averaging $225.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$18K
  • Madrigal Pharmaceuticals$6K
  • Quidel Corporation$2K
  • Medtronic$1K
  • Abiomed$486
  • Boston Scientific$197
  • plus $688 from 13 others
$78,060in research payments, 2019–2025

Across 18 payments — averaging $4336.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ortho-clinical Diagnostics, Inc.$46K
  • Quidel Corporation$32K

What the payments were for

  • Consulting fees$8,59277%
  • Food & beverage$2,53323%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,125 in reported general payments places this provider in the 70th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$102,636
Medicare patients
631
Services billed
1,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan12$18,506
Ezetimibe55$1,975
Rosuvastatin Calcium78$1,693
Metoprolol Succinate43$514
Isosorbide Mononitrate ErIsosorbide Mononitrate17$505
Atorvastatin Calcium43$418
Carvedilol12$324
Losartan Potassium43$283
ClopidogrelClopidogrel Bisulfate24$267
Valsartan13$172
Amlodipine Besylate26$90
Lisinopril12$76
Hydrochlorothiazide17$56
Amoxicillin16$24

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →